aplidin
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Anaplastic thyroid cancer (ATC) is often incurable because it doesn't respond to radioiodine, radiotherapy or chemotherapy, and…
Purpose: Aplidin (plitidespin) is a novel cyclic depsipeptide, currently in Phase II clinical trials for solid and hematologic…
Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 µM and in vivo at a dose of 0.6 mg/kg administered…
5580 Aplidin® (Plitidepsin) is an anti-tumoral agent from marine origin currently under Phase II clinical trials against multiple…
Background Anaplastic thyroid cancer (ATC) is one of the most aggressive and highly lethal human cancers. Median survival after…
Undifferentiated (anaplastic) thyroid carcinoma is a highly aggressive human cancer with very poor prognosis. Although there have…
Naturally derived anticancer agents continue to be instrumental in the systemic therapeutic intervention against solid tumors and…
To determine the potential of aplidin as a cytotoxic agent in pediatric leukemia, we tested bone marrow (BM) and peripheral blood…
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a…
Aplidin is a cell cycle inhibitor being developed by PharmaMar SA for the potential treatment of a variety of cancers, including…